The Winship Cancer Institute (Winship) has solicited extensive Input from both external and internal advisory groups and leadership committees for the planning and evaluation of its current progress, continued advancement, and the establishment of future goals and objectives. In the last reporting period, Strategically composed internal and external committees have enabled Winship to elevate the science it performs. The internal and external mechanisms discussed in this section provide essential guidance on all aspects of Winship, and include the following groups: External Planning and Evaluation: External Advisory Board (EAB), External Administrative Advisory Board, and External Clinical Trials Advisory Boards;and Internal Planning and Evaluation: Winship Internal Advisory Board, Winship Executive Committee, Scientific Research Council, Shared Resource Directors Meeting, Shared Resource Oversight Committee, Membership Committee, Shared Resource Allocation Committee, Space Resource Allocation Committee, Administrative Council, and Winship Clinical Council. Guidance and direction gathered from these many committees has been critical to the advancement of the Winship Cancer Institute. The input from these groups played a major role in the development of the 2010-2015 Winship Strategic Plan. That document has provided Winship a roadmap during the funding cycle proposed in this application. The funds requested in addition to committed institutional funds will provide support for these important advisory endeavors.
The Planning and Evaluation process has been instrumental in Winship's many successes. Each advisory structure works to ensure that Winship's priorities are understood and strategically managed to allow the cancer center to continue to develop and achieve a comprehensive set of goals.
|Goldstein, Jordan S; Nastoupil, Loretta J; Han, Xuesong et al. (2018) Disparities in survival by insurance status in follicular lymphoma. Blood 132:1159-1166|
|Richardson, Alessandra M; Havel, Lauren S; Koyen, Allyson E et al. (2018) Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell-Cancer-Associated Fibroblast Interactions during Collective Invasion. Clin Cancer Res 24:420-432|
|Jin, Lingtao; Chun, Jaemoo; Pan, Chaoyun et al. (2018) MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer Cell 34:315-330.e7|
|Guidot, Daniel M; Switchenko, Jeffrey M; Nastoupil, Loretta J et al. (2018) Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. Leuk Lymphoma 59:888-895|
|Chowdhary, Mudit; Okwan-Duodu, Derick; Switchenko, Jeffrey M et al. (2018) Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery. J Neurooncol 136:289-298|
|Chen, Zhengjia; Zheng, Youyun; Wang, Zhibo et al. (2018) Interactive calculator for operating characteristics of phase I cancer clinical trials using standard 3+3 designs. Contemp Clin Trials Commun 12:145-153|
|Halani, Sameer H; Yousefi, Safoora; Vega, Jose Velazquez et al. (2018) Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways. NPJ Precis Oncol 2:24|
|Ferris, Matthew J; Liu, Yuan; Ao, Jingning et al. (2018) The addition of chemotherapy in the definitive management of high risk prostate cancer. Urol Oncol 36:475-487|
|Halicek, Martin; Little, James V; Wang, Xu et al. (2018) Deformable Registration of Histological Cancer Margins to Gross Hyperspectral Images using Demons. Proc SPIE Int Soc Opt Eng 10581:|
|Cassidy, Richard J; Switchenko, Jeffrey M; El-Deiry, Mark W et al. (2018) Disparities in Postoperative Therapy for Salivary Gland Adenoid Cystic Carcinomas. Laryngoscope :|
Showing the most recent 10 out of 331 publications